These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22451244)

  • 1. Absorption of different oral dosage forms of oxycodone in the elderly: a cross-over clinical trial in patients undergoing cystoscopy.
    Kokki M; Välitalo P; Rasanen I; Aaltomaa S; Ojanperä I; Eskelinen M; Kokki H
    Eur J Clin Pharmacol; 2012 Oct; 68(10):1357-63. PubMed ID: 22451244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
    Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
    Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone.
    Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone.
    Mandema JW; Kaiko RF; Oshlack B; Reder RF; Stanski DR
    Br J Clin Pharmacol; 1996 Dec; 42(6):747-56. PubMed ID: 8971431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone.
    Takala A; Kaasalainen V; Seppälä T; Kalso E; Olkkola KT
    Acta Anaesthesiol Scand; 1997 Feb; 41(2):309-12. PubMed ID: 9062618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetics of oxycodone.
    Lugo RA; Kern SE
    J Pain Palliat Care Pharmacother; 2004; 18(4):17-30. PubMed ID: 15760805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
    Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
    Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic-pharmacodynamic modelling of liquid and controlled-release formulations of oxycodone in healthy volunteers.
    Ladebo L; Foster DJR; Abuhelwa AY; Upton RN; Kongstad KT; Drewes AM; Christrup LL; Olesen AE
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):263-276. PubMed ID: 31597014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer.
    Leow KP; Smith MT; Williams B; Cramond T
    Clin Pharmacol Ther; 1992 Nov; 52(5):487-95. PubMed ID: 1424423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.
    Kokki H; Rasanen I; Reinikainen M; Suhonen P; Vanamo K; Ojanperä I
    Clin Pharmacokinet; 2004; 43(9):613-22. PubMed ID: 15217304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets.
    Franke RM; Morton T; Devarakonda K
    Drug Des Devel Ther; 2015; 9():4587-97. PubMed ID: 26316698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?
    Charles B; Hardy J; Anderson H; Tapuni A; George R; Norris R
    Support Care Cancer; 2014 Feb; 22(2):325-30. PubMed ID: 24077699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
    Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
    Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.
    Benziger DP; Kaiko RF; Miotto JB; Fitzmartin RD; Reder RF; Chasin M
    J Pharm Sci; 1996 Apr; 85(4):407-10. PubMed ID: 8901078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative oxycodone pharmacokinetics in humans after intravenous, oral, and rectal administration.
    Leow KP; Smith MT; Watt JA; Williams BE; Cramond T
    Ther Drug Monit; 1992 Dec; 14(6):479-84. PubMed ID: 1485370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled Post Hoc Analysis of Population Pharmacokinetics of Oxycodone and Acetaminophen Following Multiple Oral Doses of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets.
    Morton T; Franke R; Devarakonda K
    Pain Pract; 2016 Jul; 16(6):730-6. PubMed ID: 26218586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Particle size affects pharmacokinetics of milled oxycodone hydrochloride tablet products following nasal insufflation in nondependent, recreational opioid users.
    Raofi S; Kinjo M; Sun D; Li Z; Boyce H; Natarajan K; Frost M; Zhao L; Luke M; Lionberger R; Kelsh D; Kim MJ
    Clin Transl Sci; 2021 Sep; 14(5):1977-1987. PubMed ID: 33982418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.